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Intranasal dexmedetomidine, a well-tolerated and convenient treatment option, has been
shown to induce a favorable perioperative anxiolysis in children. We investigate intranasal
dexmedetomidine as a sedative premedication for anesthesia recovery in an adult
population.
Methods
A prospective randomized controlled trial; 81 adult patients scheduled for elective suspen-
sion laryngoscopy received intranasal dexmedetomidine (1 μgkg–1) or a placebo 45–60
min before anesthetic induction. Extubation time was used as the primary outcome mea-
sure. Secondary variables included the levels of sedation (Observer’s Assessment of Alert-
ness/Sedation scale, OAA/S) and anxiety (4-point anxiety score), anesthetic and analgesic
requirements, hemodynamic fluctuations, and anesthesia recovery as well as side effects.
Results
The levels of sedation and anxiety differed significantly between the two groups at anesthe-
sia pre-induction (p < 0.001 and = 0.001, respectively). Repeated-measure general linear
model determined no significant interaction effect between group and time on the targeted
concentration of propofol (F = 1.635, p = 0.200), but a significant main effect of group
existed (F = 6.880, p = 0.010). A moderate but significant decrease in the heart rate was
recorded in the dexmedetomidine group at pre-induction. Episodes of tachycardia and
hypertension after tracheal intubation and extubation were more frequent in the placebo
group.
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Conclusions
Intranasal dexmedetomidine as a sedative premedication induced a favorable perioperative





Dexmedetomidine (DEX) is a highly selective, short-acting, alpha 2-adrenoreceptor agonist. It
can provide sedative, analgesic, and anxiolytic effects with minimal respiratory depression,
which makes it an almost-perfect adjuvant for anesthesia, as well as an ideal candidate for
relieving anxiety or nervousness before anesthesia. However, reports of adverse hemodynamic
complications, including several cases of cardiac arrest, might have hindered the widespread
use of DEX [1,2].
It has been suggested that a smaller dose or routes other than rapid intravenous delivery
may help minimize the hemodynamic risk of DEX [3,4,5,6]. The intranasal route is a conve-
nient and effective method of administration for many medications, and intranasal DEX has
been shown to have a high rate of patient acceptance [7,8,9,10]. Recently, several pediatric
studies reported beneficial perioperative outcomes of premedication with intranasal DEX
[11,12,13,14,15,16], which may indicate that it could be an alternative to traditional premedica-
tion for the pediatric population.
For adult patients, physicians might be reluctant to prescribe sedative premedications due
to concerns of delayed recovery from anesthesia. However, a Cochrane review found that there
is no evidence to support such concerns in the ambulatory setting [17]. The proper use of pre-
medication may actually decrease anesthetic and analgesic requirements as well as some side
effects, such as postoperative emesis, and thereby ultimately provide benefits in selected surgi-
cal patients [18]. There is no known link between delayed recovery and intraoperative DEX
[19,20,21]. There are, however, no scientific studies that have specifically investigated a link
between using DEX as a sedative premedication and delayed recovery from anesthesia. One
recent study compared intranasal DEX with either intranasal ketamine or a placebo in children
undergoing procedural sedation and found that both intranasal premedications were more sed-
ative and decreased times to wake and discharge compared to the placebo [22].
We conducted a randomized, double-blind, placebo-controlled study in patients who
underwent suspension laryngoscopic surgery to examine the effects of 1 μgkg–1 of intranasal
DEX on their anesthesia recovery. Previous studies conducted on healthy volunteers have indi-
cated that the studied intranasal dose is well tolerated [10,23]. Our primary outcome measure-
ment was the recovery time from general anesthesia, and other outcomes included the levels of
sedation and anxiety, anesthetic and analgesic requirements, hemodynamic parameters, post-
operative side effects, and patient satisfaction.
Materials and Methods
Following approval by the Ethics Committee of Guangzhou First Municipal People’s Hospital,
the study protocol was registered at clinicaltrials.gov (registration number NCT02108171). The
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American Society of Anesthesiologists (ASA) patients with a physical status of I or II, body
mass index (BMI)<30 kg/m2, age between 18 and 60 years, scheduled for elective suspension
laryngoscopy for the removal of benign lesions under general anesthesia betweenMarch and
June 2014 were screened for eligibility at the pre-anesthesia consultation. Written informed con-
sent was obtained from all patients at least one day before surgery. Exclusion criteria included the
following: 1) a known allergy or hypersensitivity to DEX or other anesthetics; 2) a previous his-
tory of heart disease; 3) a heart rate (HR)<45 beats per minute (bpm); 4) a second- or third-
degree atrioventricular block; 5) pregnant or breast-feeding women; 6) premenopausal women
without reliable contraception; 7) patients on antihypertensive drugs, such as α-methyldopa, clo-
nidine, or other α2-adrenergic agonists; 8) asthma, 9) sleep apnea syndrome; 10) organ dysfunc-
tion; 11) patients with mental illness; and 12) the long-term use of sedatives and analgesics.
A computer-generated list of numbers accomplished by a research member (L.L.) was used
for drug allocation. The list was concealed in opaque sealed envelopes that were numbered and
opened sequentially after obtaining the patients’ consent. A nurse who was not involved in any
other part of the study obtained the envelopes and then prepared the premedications by draw-
ing 1 μgkg–1 of DEX (Hengrui Med, Jiangsu, China; original concentration 100 μgml–1) into a
1-mL syringe and diluting it to a volume of 1 mL with 0.9% saline or the same volume of saline
as a control (CON). The appearance of DEX and CON premedications cannot be differentiated
by a third person. Test premedications (DEX or CON) were dripped into both nostrils of the
patients in a supine head down position about 45 to 60 minutes before anesthesia induction.
The patients fasted for at least 6 h and were not given other premedications. They were taught
to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 = anxious, 3 = calm,
and 4 = amiable) and satisfaction using a 3-point satisfaction score (1 = highly satisfactory,
2 = acceptable, and 3 = unacceptable). A blinded observer assessed sedation with a 7-point
modified Observer’s Assessment of Alertness/Sedation scale (OAA/S, appendix). HR and oxy-
gen saturation (SpO2) were monitored by fiber-optic pulse oximetry during patient transfer
from the ward to the operating room.
When patients arrived in the operating room, ASA standard monitoring and Narcotrend1
electroencephalography (software version 4.3; Monitor Technik, Bad Bramstedt, Germany)
were placed and recorded. Approximately 40 min following the administration of the test med-
ications, sedation and anxiety levels were recorded. Subsequently, total intravenous anesthesia
was induced via the target-controlled infusion (TCI) of propofol and remifentanil with a supply
of oxygen. After the loss of consciousness, patients received 0.6 mgkg–1 of rocuronium fol-
lowed by mask ventilation; the endotracheal tube was placed 1 min later. Mechanical ventila-
tion was adjusted to an end-tidal carbon dioxide concentration (PETCO2) of 4.0–4.7 kPa.
Propofol was infused intraoperatively to a TCI plasma concentration of 2.5 μgml–1 using
DiprifusorTM software (version 2.0, Graseby1 3500 anesthesia pump; Smiths Medical, Wat-
ford, UK). The infusion rate was adjusted via plasma concentration increments of 0.5 μgml–1
at 2-min intervals to maintain the Narcotrend index between ‘D0’ and ‘E1’ until the end of sur-
gery. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ngml–1 using the
Minto pharmacokinetic model [24] and then adjusted to maintain the systolic blood pressure
(SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuro-
muscular blockade, 0.15 mgkg–1 increments of rocuronium were infused upon observation of
the first twitch in a train-of-four response with the nerve stimulator. When the operative laryn-
goscope was removed, the propofol and remifentanil infusions were stopped simultaneously.
After surgery, the patients were transferred to the post-anesthesia care unit (PACU) and
administered neostigmine and atropine to reverse the residual neuromuscular blockade
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according to the nerve stimulator. Assisted ventilation was stopped when adequate ventilation
was confirmed: a respiratory rate (RR)>8 bpm and SpO2>90% on air for more than 5 min.
The endotracheal tube was extubated when patients met the extubation criteria and could fol-
low commands by squeezing the anesthetist’s hand.
Baseline measurements of sedation and anxiety status, non-invasive blood pressure, HR,
and oxygen staturation were collected immediately before and repeatedly after intranasal DEX
or placebo administration. The durations between intranasal dexemedetomidine and anesthe-
sia intubation as well as between anesthesia intubation and the cessation of anesthetics infusion
were recorded. In addition, we recorded the target concentrations of propofol and remifentanil
at induction (T1), before insertion (T2), and upon removal of the operative laryngoscope (T3),
at the return of spontaneous breathing (T4), at emergence (T5), and at extubation (T6). The
time elapsed between the cessation of anesthetic infusions and extubation was recorded as the
recovery time. Patient satisfaction scores were collected when patients were discharged from
the PACU. Adverse events in the peri-operative period included hypertension (SBP increased
130% of the pre-operative value for more than 1 min), hypotension (SBP decreased more than
30% of the pre-operative value for more than 1 min), tachycardia (HR>100 bpm for more
than 10 s), bradycardia (HR<45 bpm for more than 10 s), shivering, nausea, or vomiting.
When clinically indicated, 5 mg of ephedrine or 0.5 mg of atropine was administered intrave-
nously. Respiratory depression (RR<8 bpm and SpO2<90%) and analgesic requests within 2
h after extubation were recorded. In addition, an investigator who was blinded from the group-
ing (Y.Y.) asked the patients to mark their pain level on a 0–100 mm visual analogue scale
(VAS). A VAS above 50 mm was treated with intravenous 40 mg of parecoxib. Nausea or vom-
iting was treated with 4 mg of intravenous ondansetron.
Power analysis for two-group independent Student’s t-test was performed based on the
results of our pilot study in which the mean (standard deviation, SD) time to extubation was 18
(5) min. To detect a 20% difference in the time to extubation between the control and treat-
ment groups with a 5% type I error and a power of 0.9 at a 2–sided P value< 0.05, a minimum
sample size of 39 patients per group would be required. We recruited 81 patients, considering a
4% dropout rate
Statistical analyses were performed using SPSS 17.0 (SPSS Inc., Dover, Delaware, USA).
Descriptive statistics such as mean ± SD, median (extreme range), and proportions were used to
analyze patient characteristics. Assumptions of normal distribution were tested for all of the con-
tinuous variables via Shapiro-Wilk test. Student’s two-sample t test was used to analyze the anes-
thesia recovery times. Mann–WhitneyU test was used to compare the time durations between
drug administration and anesthesia intubation, anesthesia, surgery, and the OAA/S sedation score.
Repeated-measure general linear model (GLM) was calculated to assess differences in the target
concentrations of remifentanil and propofol between treatments over time. When there was an
interaction between group and time on the dependent variable, a pairwise comparisons with Bon-
ferroni adjustment was performed for each time point. The numbers of patients rating anxiety
score> 2 and satisfaction score< 2, and the episodes of adverse events, were analyzed using Fish-
er’s exact tests. A two-tailed p value less than 0.05 was considered statistically significant.
Results
We initially assessed 157 patients for eligibility. After excluding the patients who did not meet
the inclusion criteria or declined to participate, we recruited 81 patients for this randomized
study, with 41 patients allocated in the CON group and 40 patients in the DEX group, and all
the allocated patients completed this study (Fig 1). Patients’ baseline characteristics and surgi-
cal data were similar between the groups (Table 1).
Intranasal Dexmedetomidine as Premedication
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As shown in Table 2, the modified OAA/S scores were comparable among groups at base-
line and reached significantly different at the pre-induction of anesthesia (p< 0.001); after
extubation, there was no difference in sedation. Compared to the placebo group, the dexmede-
tomidine group had more patients rated anxiety score>2 at the pre-induction (p = 0.001), and
scored highly satisfactory (p = 0.015).
By using the repeated-measure GLM, we found a significant interaction effect between
group and time on the targeted concentration of remifentanil (F = 9.255, p = 0.001), and a sig-
nificant main effect of group (F = 21.402, p< 0.001). The pairwise comparisons of the concen-
tration of remifentanil showed that each time point significantly differed from each other time
Fig 1. Patient-flow diagram.
doi:10.1371/journal.pone.0154192.g001
Table 1. Baseline characteristics and surgical data of patients receiving intranasal placebo or dexmedetomidine. Values are in mean (standard devi-
ation), number (percentage), or in median (extreme range) where appropriate.
Placebo Dexmedetomidine
(n = 41) (n = 40)
Age (yr) 43.6 (9.2) 45.9 (10.1)
Weight (kg) 60.1 (10.4) 59.4 (9.1)
Height (cm) 162.2 (6.1) 162.5 (8.0)
Sex (Male: Female) 13 (31.7%): 28 (68.3%) 16 (40.0%): 24 (60.0%)
ASA status (I: II) 38 (92.7%): 3 (7.3%) 36 (90.0%): 4 (10.0%)
Duration from intranasal drug administration to arrival at operating room (min) 40 [0–78] 40 [5–100]
Duration from intranasal drug administration to anesthesia intubation (min) 54 [23–115] 55 [32–141]
Duration of anesthesia 38 [18–158] 35[16–87]
Duration of surgery (min) 18 [5–132] 18 [4–61]
doi:10.1371/journal.pone.0154192.t001
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point (all p< 0.001). There was no significant interaction effect between group and time on
the targeted concentrations of propofol (F = 1.635, p = 0.200), but the main effect of group was
significant (F = 6.880, p = 0.010), indicating intranasal dexmedetomidine reduced anesthetics
requirement of propofol. (Fig 2).
There were no significant differences noted in the time period of returning to spontaneous
breathing, conscious emergence, and tracheal extubation between the groups (Fig 3).
No significant difference in mean arterial pressure (MAP) was found between the groups. A
significant decrease in HR was noted in the DEX group at pre-induction compared to the CON
group, but no decrease of more than 20% of the baseline value, which was required for clinical
intervention, was recorded in either group at any time (S1 Fig). There were no significant dif-
ferences between the groups with regard to episodes of bradycardia and hypotension. However,
in the placebo patients, episodes of tachycardia and hypertension increased significantly after
tracheal intubation and extubation compared to the DEX group (Table 3). Fifteen patients in
the CON group and five patients in the DEX group required postoperative analgesia
(p = 0.005). Three patients from the CON group and one patient after intranasal DEX experi-
enced nausea (p = 0.623), but only one patient in the CON group was recorded as vomiting
(p = 1.0). Four patients in the CON group and one in the DEX group reported the occurrence
of postoperative shivering (p = 0.371). No intraoperative awareness was recalled.
Discussion
The principal finding of this study was that a 1-μgkg–1 intranasal dose of DEX premedication
did not delay anesthesia recovery in laryngoscopic patients. In addition, we found a number of
benefits of intranasal DEX premedication, including perioperative anxiolysis, less anesthetic
requirements, stable hemodynamics, and improved patient satisfactory outcomes.
Similar to the present study, other research on premedication with α2 agonists have indi-
cated no delayed recovery in the outcome. These investigations have included pre-anesthetic
oral clonidine among children [25] and adult patients undergoing coronary bypass [26] or gen-
eral surgery [27] as well as using 0.5–1.0 μgkg–1 of intravenous DEX [4,28,29]. However,
mixed results in recovery from premedication with both oral clonidine [30] and intravenous
DEX [31] have been reported. Intranasal administration, a noninvasive and highly convenient
method, has been used successfully to deliver DEX to children. At an appropriate dose, intrana-
sal DEX premedication has been associated with similar effects on anesthesia recovery time as
oral midazolam [12,13] or a placebo [16] in children. Previous studies have reported that intra-
nasal DEX 1–1.5μgkg–1 produced significant sedation within 45–60 min and its elimination
half-life was 114 min in healthy volunteers[7,8,9,10]. The current study was the first
Table 2. Modified OAA/S, anxiety, and satisfaction scores of patients receiving intranasal placebo or dexmedetomidine. Values showmedian (inter-
quartile range) or number of patients (percentage).
Placebo Dexmedetomidine P Value
(n = 41) (n = 40)
Modiﬁed OAA/S score
Before intranasal drugs 6 [6–6] 6 [6–6] 0.317
Pre-induction 6 [5–6] 4 [4–5] < 0.001
After extubation 4 [3–5] 4 [3–4] 0.776
Anxiety score > 2
Before intranasal drugs 23 (56.1%) 25 (62.5%) 0.558
Pre-induction 29 (70.7%) 39 (97.5%) 0.001
Satisfaction score < 2 25 (61.0%) 34 (85.0%) 0.015
doi:10.1371/journal.pone.0154192.t002
Intranasal Dexmedetomidine as Premedication
PLOS ONE | DOI:10.1371/journal.pone.0154192 May 19, 2016 6 / 12
randomized controlled study to determine the effects of intranasal DEX premedication on
adult patients’ recovery from general anesthesia.
Several mechanisms may explain a few of the adverse effects of DEX premedication on anes-
thesia recovery in the present study. First, the anesthetic-sparing properties and analgesic qual-
ities of DEX have been positively associated with anesthesia recovery. Its additive or synergistic
role in intraoperative anesthesia and its potential analgesic effect of alleviating postoperative
Fig 2. Predicted effect-site concentrations of propofol (a) and remifentanil (b) after intranasal placebo or dexmedetomidine.The
target concentrations of propofol or remifentanil were recorded at induction (T1), before insertion (T2), and upon removal of the
operative laryngoscope (T3), at the return of spontaneous breathing (T4), at emergence (T5), and at extubation (T6). TCI stands
for target-controlled infusion. Error bars represent standard deviation.
doi:10.1371/journal.pone.0154192.g002
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PLOS ONE | DOI:10.1371/journal.pone.0154192 May 19, 2016 7 / 12
Fig 3. Anesthesia recovery times were similar between patients receiving intranasal placebo and those receiving
dexmedetomidine. The times elapsed between stopping anesthetic infusions and adequate ventilation, consciousness,
and extubation were also recorded as time to spontaneous breathing, emergency, and time to extubation. Error bars
represent standard deviation.
doi:10.1371/journal.pone.0154192.g003
Table 3. Patients with cardiovascular adverse episodes in two groups. Values represent numbers of patients.
Placebo Dexmedetomidine P Value
(n = 41) (n = 40)
Bradycardiac episode
Pre-induction 0 2 0.241
After intubation 1 1 1
Intraoperative 5 3 0.737
After extubation 5 7 0.502
Tachycardiac episode
Pre-induction 0 0 1
After intubation 8 1 0.037
Intraoperative 11 5 0.105
After extubation 9 2 0.026
Hypotensive episode
Pre-induction 0 2 0.241
After intubation 3 4 0.973
Post-induction 3 4 0.973
After extubation 1 0 1
Hypertensive episode
Pre-induction 1 0 1
After intubation 6 0 0.037
Intraoperative 6 5 0.779
After extubation 14 5 0.022
doi:10.1371/journal.pone.0154192.t003
Intranasal Dexmedetomidine as Premedication
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pain may expedite early recovery. Regarding residual sedation, intranasal DEX premedication
may have the same residual effect in the immediate postoperative period as its intravenous
administration. Previous data from healthy volunteers revealed that both administration routes
of DEX had a similar elimination half-life (t1/2) with a median (range) of 114 (107–151) and
115 (99–145) min, respectively, and had comparable sedation effects as well [10]. A multicenter
trial assessed DEX by intravenous loading doses and maintenance infusion for procedure seda-
tion and reported a favorable recovery outcome over placebo [32]. It is likely that a pre-anesthetic
intranasal administration would leave a lower accumulated plasma concentration of DEX or less
residual sedation in the immediate postoperative period than an intravenous loading dose fol-
lowed by a maintenance infusion. Furthermore, the use of a small dose of DEX intranasally may
also contribute to a favorable recovery. We and others have previously reported this favorable
association between low-dose DEX given intravenously at pre-anesthetic time and anesthesia
recovery [4,28,29]. In the present study, intranasally low-dose DEX administration, as previously
described elsewhere [7,8,9], induced mild but clinically favorable sedation compared to the pla-
cebo. Although a larger dose of intranasal DEX has been shown to be more effective in pre-anes-
thetic sedation, the expense is that it would delay recovery in pediatric patients [16].
The hemodynamic parameters of intranasal DEX are noteworthy. Reports of hypotension,
bradycardia, and significant cardiovascular dysfunction have been associated with DEX infu-
sion. In this study, we also noted a decrease in HR and SBP at anesthesia pre-induction in the
DEX-premedicated patients. However, the decrease in both HR and SBP was mild or moderate
and well tolerated in our relatively young and healthy patients without requirement of clinical
intervention. Previous studies using intranasal DEX reported similar manageable hemody-
namic responses [7,8,9,10]. In addition, we found that the hemodynamic response to tracheal
intubation and extubation was attenuated in the DEX-premedicated patients. We speculate
that the dose reduction and the specified intranasal route of administration may help mitigate
the hemodynamic instabilities of DEX. A case report published at the completion of this clini-
cal trial [33] noted that a high dose of intranasal DEX (~2.4 μgkg–1) caused severe bradycardia
in a pediatric patient, indicating that a large intranasal dose of DEX to achieve deep sedation
should be administrated cautiously.
This study has several limitations. First, sprayed or atomized delivery can markedly improve
uptake, the time to onset, and the pharmacological efficacy of intranasal medication when
compared with the syringe nasal drops used in our study. Nevertheless, the syringe nasal
method has been used in many studies and has been found to be a cost-effective drug delivery
technique in experienced hands and with cooperative patients [34,35]. Second, this study
involved relatively healthy and young participants. Although there have been a few reports on
the pharmacokinetics and pharmacodynamics of intranasal DEX, the absolute bioavailability
remains as yet largely under-investigated. The effects of intranasal DEX may differ with co-
existing diseases, elderly patients, and various surgical stimulations. Third, target concentra-
tions were used to assess the intraoperative requirements of propofol and remifentanil. If the
plasma concentrations were to be measured, the anesthetic and analgesic sparing effects would
be more convincing. However, the pharmacokinetic models we applied are now well estab-
lished. Four, Although none of the enrolled patients had epistaxis, ulcer, infection, deviated
septum, or trauma, criteria should exclude those patients with any of these oblivious nasal
abnormality before trial recruitment.
In conclusion, intranasal DEX at a dose of 1 μgkg–1 as a sedative premedication has demon-
strated a favorable perioperative anxiolysis without prolongation in anesthesia recovery, and its
hemodynamic effect was well tolerated by the patients included in this study. Intranasal DEX
can be considered another premedication alternative to manage selected patients with pre-
anesthesia anxiety.
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Appendix
Modified Observer’s Assessment of Alertness/Sedation Scale
6. Appears alert and awake, responds readily to name spoken in normal tone
5. Appears asleep but responds readily to name spoken in normal tone
4. Lethargic response to name spoken in normal tone
3. Responds only after name is called loudly or repeatedly
2. Responds only after mild prodding or shaking
1. Does not respond to mild prodding or shaking
0. Does not respond to noxious stimulus
Supporting Information
S1 Fig. Haemodynamics fluctuations.Heart rate (a) and mean arterial pressure fluctuations
(b) after intranasal placebo or dexmedetomidine. In comparison with baseline levels, heart rate
increased at T4–5 in the placebo group (p = 0.000 and 0.023, respectively) but decreased at T2–
3 and T7–10 in the dexmedetomidine group (p = 0.038, 0.002, 0.011, 0.034, 0.001, and 0.003,
respectively). No significant difference in mean arterial pressure between the groups. In com-
parison with baseline levels, mean arterial pressure increased at T2, 7–10 in the placebo group
(p = 0.004, 0.033, 0.000, 0.000, 0.003, respectively) and at T9 in the dexmedetomidine group
(p = 0.019). Data points were shifted horizontally to avoid overlapping. Error bars represent
standard deviation. T1, before intranasal drops; T2, on arrival at the operating room; T3, at
pre-induction; T4, after tracheal intubation; T5, after inserting operative laryngoscope; T6,
after removal of laryngoscope; T7, on arrival at the post-anaesthesia unit; T8, at emergency;
T9, after extubation; T10, before leaving the post-anaesthesia unit.
(DOCX)
S1 File. Consort Checklist.
(DOCX)
S2 File. Protocol translation. This is trial protocol in English.
(DOCX)
S3 File. Protocol. This is original protocol in Chinese
(DOCX)
S4 File. Informed Consent Form. This is original Informed Consent Form for this trial.
(DOCX)
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